AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39112102
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g TID during the OLP
Trial: 39112464
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan (SG) at 10 mg/kg, administered as a single intravenous dose one day before resection and continued on days 1 and 8 of 21-day cycles following recovery.
Trial: 39112489
Drug: 4CMenB (Bexsero,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (Bexsero, GSK) vaccine, two doses
Trial: 39112489
Drug: 4CMenB (Bexsero,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (Bexsero, GSK) vaccine
Trial: 39112628
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg weekly for 12 months (N=10)
Trial: 39113067
Drug: Rosuvastatin (when
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (when LDL-C < 70 mg/dL)
Trial: 39113067
Drug: Atorvastatin (when
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (when LDL-C < 70 mg/dL)
Trial: 39113190
Drug: Neoadjuvant AC-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant AC-T chemotherapy with metformin
Trial: 39113266
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for urinary incontinence treatment
Trial: 39114274
Drug: Sutimlimab (C1s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutimlimab (C1s inhibitor), biweekly doses for up to 1 year after Part A
Trial: 39114536
Drug: THC/CBD combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD combination
Trial: 39114536
Drug: THC alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC alone, CBD alone, THC/CBD combination, Placebo
Trial: 39114870
Drug: Zanidatamab treatment
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab treatment (administered once every 2 weeks)
Trial: 39114870
Drug: Zanidatamab treatment
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab treatment
Trial: 39115062
Drug: Nipocalimab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab (30 or 45 mg per kilogram of body weight per week) administered from 14 to 35 weeks' gestation
Trial: 39115062
Drug: Nipocalimab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipocalimab treatment
Trial: 39115419
Drug: mRNA-4157 (1-mg)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-4157 (1-mg)
Trial: 39115419
Drug: mRNA-4157 (1-mg)
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-4157 (1-mg) + Pembrolizumab (200-mg)
Trial: 39115608
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention (information campaigns on AF diagnosis and therapies)
Trial: 39116153
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine therapy
Trial: 39116333
Drug: CETA-PWH (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETA-PWH (moderate dose)
Trial: 39116435
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control program (computer games designed for entertainment, e.g., Solitaire)
Trial: 39116448
Drug: ML models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ML models (eXtreme Gradient Boosting, Feedforward Neural Network, Logistic Regression, Support Vector Machine)
Trial: 39116486
Drug: Quadrivalent inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent inactivated influenza vaccine (IIV4) - three manufacturing lots, single dose.
Trial: 39116902
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 5·4 mg/kg
Trial: 39116902
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 6·4 mg/kg
Trial: 39116904
Drug: Butantan-DV (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butantan-DV (0.5 mL single dose)
Trial: 39117488
Drug: PEG-EPO (0.2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-EPO (0.2, 0.4, 0.8, 1.6, 2.4, 3.6, or 4.8 µg/kg)
Trial: 39117670
Drug: Nivolumab 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360 mg iv on day 1, carboplatin AUC 5 iv on day 1, etoposide 100 mg/m2 iv on days 1-3
Trial: 39117964
Drug: Glibenclamide 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 3.75 mg/day for 7 days
Trial: 39118415
Drug: Treatment interventions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interventions for neonatal complications
Trial: 39119004
Drug: Lugol's solution
RxNorm normalized name: Lugol's Solution
DrugBank: Potassium triiodide (DB14492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol's solution 5%, three oral drops thrice daily for 10 days
Trial: 39120779
Drug: Project Share
RxNorm normalized name: shark preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project Share (Supportive Therapy)
Trial: 39120902
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for insomnia integrated in best-evidence pain management (CBTi-BEPM)
Trial: 39121478
Drug: Automated SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated SMS text message intervention, 2 daily messages for 4 weeks
Trial: 39121698
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of Ad26.COV2·S
Trial: 39122384
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lactoferrin and lysozyme
Trial: 39122389
Drug: Dose-volume constraints
RxNorm normalized name: Constrained Metal (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-volume constraints derived from statistical model in PredicT A
Trial: 39122389
Drug: Dose-volume constraints
RxNorm normalized name: Constrained Metal (Curcuma Longa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-volume constraints tested in PredicT B
Trial: 39122788
Drug: m-DOT (mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-DOT (mobile Directly Observed Therapy) with hydroxyurea (15 mg/kg daily for three months)
Trial: 39122788
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring with hydroxyurea (15 mg/kg daily for three months)
Trial: 39125394
Drug: Teduglutide (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide (0.05 mg/kg/day)
Trial: 39125394
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition and/or intravenous fluids (mean volume)
Trial: 39125451
Drug: Glycocalyx dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycocalyx dietary supplement (GDS), n = 25
Trial: 39126603
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) formulation of donepezil at doses of 70, 140, and 280 mg
Trial: 39126603
Drug: Oral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulation of donepezil at 10 mg
Trial: 39126720
Drug: Clazosentan (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (15 mg/hour intravenous)
Trial: 39126937
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg daily
Trial: 39126937
Drug: Melatonin 3
RxNorm normalized name: melatonin 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 3 mg daily
Trial: 39127745
Drug: Atezolizumab in
RxNorm normalized name: atezolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab in combination with chemotherapy with or without bevacizumab
Trial: 39128498
Drug: Methionine test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine test intake (range: 0-40 mg⋅kg) during early gestation (11-20 weeks)
Trial: 39128498
Drug: Methionine test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine test intake (range: 0-40 mg⋅kg) during late gestation (31-40 weeks)
Trial: 39538331
Drug: Neoantigen DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoantigen DNA vaccine
Trial: 39129005
Drug: Oral Myofunctional
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Myofunctional Therapy (OMT)
Trial: 39129619
Drug: Lugol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol solution (7 days treatment)
Trial: 39129619
Drug: No Lugol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Lugol treatment (control group)
Trial: 39130023
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) detectable in 80.7% of patients; median hs-cTnT 10 ng/L (IQR: 6-18 ng/L)
Trial: 39130025
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy for AF in cancer patients
Trial: 39130140
Drug: Intravascular lithotripsy
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular lithotripsy (IVL) as an adjunct to coronary stenting
Trial: 39131140
Drug: Erlotinib 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 75 mg/day
Trial: 39131140
Drug: Erlotinib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 50 mg/day
Trial: 39131140
Drug: Erlotinib 25
RxNorm normalized name: erlotinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 25 mg/day
Trial: 39131144
Drug: Oral 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 8 mg insulin
Trial: 39131668
Drug: Colesevelam administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam administered with mixed meal tests
Trial: 39132049
Drug: Canocapavir 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 25 mg
Trial: 39132049
Drug: Canocapavir 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 75 mg
Trial: 39132049
Drug: Canocapavir 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 150 mg
Trial: 39132049
Drug: Canocapavir 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 300 mg
Trial: 39132049
Drug: Canocapavir 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 450 mg
Trial: 39132049
Drug: Canocapavir 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 75 mg (multiple ascending dose)
Trial: 39132049
Drug: Canocapavir 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 150 mg (multiple ascending dose)
Trial: 39132049
Drug: Canocapavir 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canocapavir 300 mg (multiple ascending dose)
Trial: 39132075
Drug: Low-residue diet
RxNorm normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-residue diet (LRD) (<10 g fiber per day)
Trial: 39132187
Drug: Prescription Digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Digital Therapeutic (PDT) containing cognitive behavioral therapy for 90 days
Trial: 39133474
Drug: Oral apixaban,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily
Trial: 39133474
Drug: Oral aspirin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin, 81 mg, once daily
Trial: 39133474
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of apixaban vs aspirin among those with cancer
Trial: 39133680
Drug: Standardized pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized pain medication tapering program
Trial: 39133680
Drug: Personalized pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized pain medication tapering program
Trial: 39133680
Drug: No tapering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tapering program
Trial: 39134085
Drug: Intraurethral LBP-EC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraurethral LBP-EC01 (2 days) and intravenous LBP-EC01 (1×10) for 3 days
Trial: 39134346
Drug: Neoadjuvant anti-PD-1
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant anti-PD-1 therapy
Trial: 39134346
Drug: Supplement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement of anti-TIM-3
Trial: 39134346
Drug: Tumor and
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor and paired lung samples from treatment-naïve patients
Trial: 39134434
Drug: Low-dose sesame
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose sesame oral immunotherapy (OIT) with a 300 mg maintenance dose of sesame protein administered once daily for up to 18 months
Trial: 39134434
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including an elimination diet and observation for 1 year
Trial: 39134434
Drug: Low-dose sesame
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose sesame oral immunotherapy (OIT)
Trial: 39134434
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including an elimination diet
Trial: 39134652
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4)
Trial: 39134652
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C5)
Trial: 39134652
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4 and C5 combined)
Trial: 39134667
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk (2 ml orally)
Trial: 39135126
Drug: Minodronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minodronate (1 mg/day)
Trial: 39135209
Drug: Mesenchymal stromal/stem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal/stem cells (MSCs) therapy
Trial: 39135452
Drug: Tofacitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib treatment from baseline to week 18
Trial: 39135540
Drug: Efzimfotase alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efzimfotase alfa (15 mg, 45 mg, or 90 mg) administered as one intravenous (i.v.) dose followed by 3 weekly subcutaneous (s.c.) doses.
Trial: 39136011
Drug: Zerafil (omalizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zerafil (omalizumab biosimilar) administered at a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level and body weight every two or four weeks for 28 weeks.
Trial: 39136011
Drug: Omalizumab (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (reference product) administered at a standard dose.
Trial: 39136260
Drug: Daily headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily headache diary
Trial: 39136560
Drug: Selective prostatic
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective prostatic arterial administration of gallium 68 PSMA PET/CT radioligand
Trial: 39136560
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of gallium 68 PSMA PET/CT radioligand
Trial: 39136801
Drug: TransCon PTH
RxNorm normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon PTH treatment
Trial: 39137167
Drug: Oral resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol (40 mg twice a day for 1 week, then 20 mg twice a day for 6 months)
Trial: 39137167
Drug: Matched oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched oral placebo
Trial: 39137185
Drug: Self-sampling kits
RxNorm normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-sampling kits offered to women overdue for cervical cancer screening (CC) during breast cancer screening.
Trial: 39137185
Drug: Self-sampling offered
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-sampling offered to women overdue for CC screening.
Trial: 39137617
Drug: In-beam Positron
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-beam Positron Emission Tomography (PET) monitoring during carbon therapy
Trial: 39137624
Drug: Ketone ester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone ester (25 g bis-octanoyl (R)-1,3-butanediol)
Trial: 39138024
Drug: Fetal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal therapy (including thoracoamniotic shunts, antenatal steroids, and combination therapies)
Trial: 39138436
Drug: Erdafitinib 8
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib 8 mg once daily (with option for up-titration to 9 mg) or 10 mg (7 days on/7 days off for 4 NSCLC patients)
Trial: 39138719
Drug: Active PPF-block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PPF-block (5-mL injectates of 20 mg of ropivacaine plus 4 mg of dexamethasone)
Trial: 39138719
Drug: Placebo PPF-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PPF-injection (saline solution)
Trial: 39138719
Drug: Placebo PPF-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PPF-injection
Trial: 39138826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miR-151a-3p or miR-21-5p with leptin
Trial: 39138826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miR-151a-3p with glucose
Trial: 39138826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miR-126-5p with leptin
Trial: 39139218
Drug: Vedolizumab (week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (week 6 serum concentration >41.65 µg/ml)
Trial: 39139269
Drug: Early vitrectomy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early vitrectomy surgery in addition to antibiotic administration
Trial: 39139269
Drug: Intravitreal antibiotic
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal antibiotic administration alone (standard of care)
Trial: 39139270
Drug: tezacaftor-ivacaftor (TEZ/IVA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tezacaftor-ivacaftor (TEZ/IVA), 28 days treatment duration
Trial: 39139270
Drug: placebo, 28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 28 days treatment duration
Trial: 39140289
Drug: Safusidenib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safusidenib treatment following biopsy and prior to surgical resection
Trial: 39140727
Drug: Caffeine loading
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine loading dose
Trial: 39141364
Drug: Baricitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (both doses)
Trial: 39141378
Drug: Verinurad plus
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad plus Allopurinol (12 mg plus 300 mg)
Trial: 39141577
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg every 2 weeks (dose-escalation cohort)